Business:Investing
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
And AbbVie has filed a suit in the U.S. against BeiGene, one of China’s most up-and-coming young drug makers. What’s likely to happen next in this tug of war between the two companies’ similar blood cancer drugs? Exactly how expensive and destructive are such lawsuits to the companies involved?
More Episodes
A Bagel Success Story, and a Red Bull Slayer
2025-04-29
21
2025-04-29
21
Delisting Speculation, and a New Tea Listing
2025-04-23
23
2025-04-23
23
Fintech Lender Rebound, and a Hotel Mess
2025-04-15
21
2025-04-15
21
TikTok in Limbo, and Xiaomi's EV Crisis
2025-04-08
18
2025-04-08
18
A Hydrogen Listing, and a New China Toy Story
2025-04-01
24
2025-04-01
24
Soaring Stock Brokers, and Rising Tobacco
2025-03-26
27
2025-03-26
27
New solar policy support, and a stock market cleanup
2025-03-18
30
2025-03-18
30
The Nationalism Factor, and a Forced Asset Sale
2025-03-13
35
2025-03-13
35
China's Takeout Delivery Market Gets a Shakeup
2025-03-04
33
2025-03-04
33
McKinsey Weighs China Exit, and Shenzhen Rescues Vanke
2025-02-11
36
2025-02-11
36
What's Ahead for China Inc. Under Trump 2.0?
2025-01-21
43
2025-01-21
43
Bubble Tea IPOs Come Back, and an Nvidia Supplier Booms
2024-12-31
28
2024-12-31
28
GM’s China Charge, and Nvidia’s Antitrust Probe
2024-12-17
34
2024-12-17
34
Two IPOs: One in Autonomous Driving and One in Gold
2024-12-10
30
2024-12-10
30
Get this podcast on your
phone, FREE
